Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City from September 9-11, 2024. The company's management team will engage in one-on-one meetings with investors and take part in a fireside chat and Q&A session on Tuesday, September 10, at 10:30 AM EST.
This event provides an opportunity for Aurinia to showcase its developments and interact with potential investors. However, it's worth noting that the fireside chat and Q&A session will not be webcast, limiting access to attendees present at the conference.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annuale sugli Investimenti H.C. Wainwright a New York City dal 9 all'11 settembre 2024. Il team di gestione dell'azienda parteciperà a incontri one-on-one con gli investitori e prenderà parte a una chiacchierata informale e a una sessione di domande e risposte martedì 10 settembre alle 10:30 AM EST.
Questo evento offre un'opportunità per Aurinia di mostrare i suoi sviluppi e interagire con potenziali investitori. Tuttavia, è importante notare che la chiacchierata informale e la sessione di domande e risposte non saranno trasmesse in streaming, limitando così l'accesso solo ai partecipanti presenti alla conferenza.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) ha anunciado su participación en la 26ª Conferencia Global Anual de Inversiones H.C. Wainwright en la ciudad de Nueva York del 9 al 11 de septiembre de 2024. El equipo de gestión de la compañía se reunirá en encuentros individuales con inversores y participará en una charla informal y una sesión de preguntas y respuestas el martes 10 de septiembre a las 10:30 AM EST.
Este evento brinda a Aurinia la oportunidad de mostrar sus desarrollos e interactuar con inversores potenciales. Sin embargo, vale la pena señalar que la charla informal y la sesión de preguntas y respuestas no se transmitirán en línea, lo que limita el acceso a los asistentes presentes en la conferencia.
아우리니아 제약 주식회사 (NASDAQ: AUPH)는 2024년 9월 9일부터 11일까지 뉴욕에서 열리는 H.C. 웨인라이트 제26회 글로벌 투자 컨퍼런스에 참가한다고 발표했습니다. 회사 관리팀은 투자자와 일대일 회의를 진행하고 9월 10일 화요일 오전 10시 30분 EST에 라운드 테이블 대화 및 Q&A 세션에 참여할 예정입니다.
이 행사는 아우리니아가 자사의 개발 내용을 선보이고 잠재적 투자자와 상호작용할 수 있는 기회를 제공합니다. 그러나 라운드 테이블 대화와 Q&A 세션은 웹캐스트되지 않으므로, 컨퍼런스에 참석하는 사람들만이 접근할 수 있습니다.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright à New York du 9 au 11 septembre 2024. L'équipe de direction de l'entreprise tiendra des réunions individuelles avec des investisseurs et participera à une discussion informelle ainsi qu'à une séance de questions-réponses le mardi 10 septembre à 10h30 EST.
Cet événement offre à Aurinia l'opportunité de présenter ses développements et d'interagir avec des investisseurs potentiels. Cependant, il convient de noter que la discussion informelle et la séance de questions-réponses ne seront pas diffusées en direct, limitant l'accès aux personnes présentes à la conférence.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright in New York City vom 9. bis 11. September 2024 bekannt gegeben. Das Management-Team des Unternehmens wird persönliche Treffen mit Investoren abhalten und an einem informellen Gespräch sowie einer Q&A-Sitzung am Dienstag, dem 10. September um 10:30 Uhr EST teilnehmen.
Diese Veranstaltung bietet Aurinia die Möglichkeit, seine Entwicklungen zu präsentieren und mit potenziellen Investoren zu interagieren. Es ist jedoch zu beachten, dass das informelle Gespräch und die Q&A-Sitzung nicht im Internet übertragen werden, was den Zugang auf die anwesenden Teilnehmer der Konferenz beschränkt.
- None.
- None.
Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Tuesday, September 10, at 10:30 AM EST. This session will not include a webcast.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828651786/en/
Media & Investor Inquiries:
Andrea Christopher,
Corporate Communications & Investor Relations, Aurinia
achristopher@auriniapharma.com
General Investor Inquiries:
ir@auriniapharma.com
Source: Aurinia Pharmaceuticals Inc.
FAQ
When is Aurinia Pharmaceuticals (AUPH) participating in the H.C. Wainwright Global Investment Conference?
What activities will Aurinia Pharmaceuticals (AUPH) engage in during the investment conference?
Will there be a webcast of Aurinia Pharmaceuticals' (AUPH) fireside chat at the H.C. Wainwright conference?
Where is the H.C. Wainwright Global Investment Conference that Aurinia Pharmaceuticals (AUPH) is attending taking place?
